Pharmafile Logo

B2B sales

- PMLiVE

bluebird bio sells Rare Pediatric Disease Priority Review Voucher

The company was granted two PRVs upon the FDA approvals of Zynteglo and Skysona

- PMLiVE

Scientists identify vital role of enzyme in survival of certain cancers

The results offer the foundations for a clinical trial evaluating the effects of POLQ inhibitors

- PMLiVE

Concerns about data security are building a strong case for clinical mobility in EMEA

Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug shown to slow memory decline in confirmatory study

The findings have been described as a ‘major step forward’ for dementia research

- PMLiVE

Gilead’s Biktarvy received EC approval for the treatment of HIV in paediatric populations

After changing to Biktarvy, 98% of patients in two groups were suppressed at week 48

- PMLiVE

GSK’s new global survey exposes lupus treatment gaps

The findings show opportunities to address organ damage risk for early stage lupus patients

- PMLiVE

Cancer Research Horizons and the Karolinska Institutet announce five-year strategic partnership

The collaboration will aim to accelerate the translation of cancer research into clinical practice

- PMLiVE

MHRA approves LEO Pharma’s Adtralza for adolescent patients with atopic dermatitis

The changes to the terms were also approved by the EC in October

- PMLiVE

DIGITAL HEALTH IN PRACTICE AND OVERCOMING DIGITAL FATIGUE

During this year’s Reuters event, Pharma 2022, WebMD CMO, Dr John Whyte discussed the ways in which digital health is growing, and the importance of educating clinicians in the right...

Medscape Education

- PMLiVE

Developing a portfolio strategy

Approaches to portfolio strategy have become more holistic across the healthcare industry, but what are the benefits for business?

- PMLiVE

AstraZeneca to acquire Neogene Therapeutics in $320m deal

The agreement will build the company’s pipeline of cell-based cancer treatments

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links